Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind,Placebo-Controlled Evaluation of the Safety and Efficacy of Neramexane Monotherapy in Patients With Moderate to Severe Dementia of the Alzheimer's Type

NCT00090116 is registered in ClinicalTrials.gov with Forest Laboratories as lead sponsor.

NCT NCT00090116
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00090116 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind,Placebo-Controlled Evaluation of the Safety and Efficacy of Neramexane Monotherapy in Patients With Moderate to Severe Dementia of the Alzheimer's Type
Lead sponsor
Forest Laboratories
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2003
Completion date
March 31, 2005
Enrollment
400
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease